Immunome
Open
$18.31
Prev. Close
$18.31
High
$18.39
Low
$18.23
Market Snapshot
$2.08B
-9.3
-5.17
$9.04M
206
Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. The company is headquartered in Bothell, Washington and currently employs 117 full-time employees. The company went IPO on 2020-10-02. The firm is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The firm's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.
Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. The company is headquartered in Bothell, Washington and currently employs 117 full-time employees. The company went IPO on 2020-10-02. The firm is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The firm's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.
Recently from Cashu
Aro Biotherapeutics Appoints Dr. Sarma, Formerly of Immunome, to Lead siRNA Innovations
Aro Biotherapeutics Welcomes New Leadership to Drive siRNA Innovations Aro Biotherapeutics, a clinical-stage biotechnology company specializing in targeted short-interfering RNA (siRNA) medicines, und…
Immunome Expands Team with Stock Options to Enhance Cancer Therapy Development
Immunome Strengthens Talent Pool with New Inducement Awards Immunome, Inc., a biotechnology company based in Bothell, Washington, is making significant strides in its commitment to advancing targeted…
Immunome Expands Workforce to Enhance Cancer Therapy Development and Pipeline Progress
Immunome Expands Workforce to Accelerate Cancer Therapy Development Immunome, Inc., a biotechnology firm focused on innovative cancer treatments, announces the addition of four new employees as part o…
Immunome Raises $172.5 Million to Advance Targeted Cancer Therapies Development
Immunome Secures Significant Funding to Propel Cancer Therapy Development Immunome, Inc., a biotechnology firm based in Bothell, Washington, has successfully completed an underwritten public offering,…